Tools for fragment based drug discovery



Gregg Siegal – CEO

Gregg obtained his PhD on studies of eukaryotic DNA replication at the University of Rochester in the USA. Pursuing an interest in structural biology, he moved to the laboratory of Professor Kurt Wüthrich at the ETH in Zürich, Switzerland. His work in the Wüthrich group focused on heteronuclear NMR studies of protein structure and folding. Subsequently he joined the group of Professor Paul Driscoll at the Ludwig Institute of Cancer Research in London, UK where he studied protein structure and small molecule interactions, again using NMR.

He moved to Leiden University in 1997 where he received a Dutch Royal Society Fellowship to form his own research group. His current research interests focus on development of drug discovery technologies and their implementation in the drug discovery process. In 2004 he spun out ZoBio to commercialize the TINS ligand screening technology developed in his group and presently serves as the Chief Executive Officer in addition to his position within the University.

Rob Heetebrij – COO

Rob co-founded ZoBio in 2004 and is the Chief Operations Officer. Prior to founding ZoBio he held various positions at Kreatech Biotechnology, an Amsterdam based Diagnostics Company. In a time frame of 8 years he evolved from R&D scientist into group leader with project management and IP strategy responsibilities, the last 2-3 years he was R&D manager with some 25 staff and member of the management team.

Rob has a PhD degree from Leiden University in bio-inorganic chemistry in the field of platinum antitumor drug research; he has authored more than 20 peer-reviewed scientific publications and is the inventor of 6 patent families.